- Conditions
- Melanoma Stage IV, Solid Tumor
- Interventions
- GIM-531, Anti-PD-1 monoclonal antibody
- Drug
- Lead sponsor
- Georgiamune Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • Bakersfield, California • Fullerton, California + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 745–768
of 1,115
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exenatide Once Weekly, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 14,752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 139
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 124 more
- Conditions
- Myelofibrosis (MF)
- Interventions
- Navitoclax, Ruxolitinib, Best Available Therapy (BAT)
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 41
- States / cities
- Chandler, Arizona • Springdale, Arkansas • Duarte, California + 34 more
- Conditions
- Moderate-to-Severe Atopic Dermatitis
- Interventions
- Placebo, Nemolizumab
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 941 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 57
- States / cities
- North Little Rock, Arkansas • Cerritos, California • Fountain Valley, California + 48 more
- Conditions
- Sjogrens Disease
- Interventions
- Abatacept, Placebo
- Biological · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 19
- States / cities
- Fullerton, California • Riverside, California • Lakewood, Colorado + 14 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- linagliptin, glimepiride, linagliptin placebo, glimepiride placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 6,103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 177
- States / cities
- Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 139 more
- Conditions
- Central Line Associated Blood Stream Infections (CLABSI)
- Interventions
- Infection Preventionist Led Best Practices Reminders
- Behavioral
- Lead sponsor
- Swedish Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 19
- States / cities
- Anchorage, Alaska • Apple Valley, California • Burbank, California + 15 more
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Interventions
- Rucaparib, Placebo
- Drug
- Lead sponsor
- pharmaand GmbH
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Fullerton, California • Sacramento, California + 18 more
- Conditions
- Amblyopia
- Interventions
- Not listed
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 3 Years to 6 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Fullerton, California
- Conditions
- Early Detection of Cancer, Cancer
- Interventions
- MCED, SOC
- Other
- Lead sponsor
- GRAIL, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 14,633 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Burbank, California • Fullerton, California + 13 more
- Conditions
- Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
- Interventions
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, Abemaciclib
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2029
- U.S. locations
- 784
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 511 more
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Biospecimen Collection, Computed Tomography with Contrast, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Osimertinib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 347
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 238 more
- Conditions
- Amblyopia
- Interventions
- Atropine, Plano lens
- Drug · Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 3 Years to 7 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Fullerton, California • Durham, North Carolina
- Conditions
- Healthy
- Interventions
- 3D OCT-1 Maestro
- Device
- Lead sponsor
- Topcon Medical Systems, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 504 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Fullerton, California • Livermore, California + 4 more
- Conditions
- Colorectal Cancer, Neoplasms, Colorectal
- Interventions
- CS7017, irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 6
- States / cities
- Beverly Hills, California • Fullerton, California • Washington D.C., District of Columbia + 3 more
- Conditions
- Breast Cancer
- Interventions
- gemcitabine/carboplatin, Iniparib
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 519 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 102
- States / cities
- Birmingham, Alabama • Sedona, Arizona • Jonesboro, Arkansas + 98 more
- Conditions
- Diabetes Mellitus
- Interventions
- Exubera, Randomized diabetes therapy
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,439 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 131
- States / cities
- Bay Minette, Alabama • Graysville, Alabama • Pell City, Alabama + 111 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- sigvotatug vedotin, docetaxel
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 762 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 130
- States / cities
- Anchorage, Alaska • Fullerton, California • Los Alamitos, California + 91 more
- Conditions
- Irritable Bowel Syndrome With Diarrhea (IBS-D)
- Interventions
- MD-7246, Placebo
- Drug
- Lead sponsor
- Ironwood Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 80
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 65 more
- Conditions
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease
- Interventions
- Dasatinib, Imatinib Mesylate, Laboratory Biomarker Analysis, Nilotinib, Pembrolizumab
- Drug · Other · Biological
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2031
- U.S. locations
- 291
- States / cities
- Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 209 more
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Venetoclax, Cyclophosphamide, Obinutuzumab, Rituximab, Doxorubicin, Vincristine, Prednisone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 9
- States / cities
- Fullerton, California • Los Angeles, California • Santa Maria, California + 6 more
- Conditions
- No Eye Disease
- Interventions
- Not listed
- Lead sponsor
- Optovue
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 4
- States / cities
- Fullerton, California • Pomona, California • San Jose, California + 1 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Dacomitinib (PF-00299804), Active Comparator (erlotinib), Placebo erlotinib, Placebo PF00299804
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 878 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Florence, Alabama • Mobile, Alabama + 65 more
- Conditions
- Breast Cancer
- Interventions
- Amcenestrant-matching placebo, SAR439859, Palbociclib, Letrozole, Goserelin, Letrozole-matching placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,068 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 45
- States / cities
- Daphne, Alabama • Glendale, Arizona • Tucson, Arizona + 40 more